In This Section
Invex Therapeutics
Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
IIH EVOLVE
IIH EVOLVE is a randomised, placebo-controlled, double-blind Phase III clinical trial that will randomise 240 adult patients with newly diagnosed IIH with papilloedema to determine the efficacy and safety of Presendin versus placebo, administered once weekly over 24 weeks.
To find out more about this phase III clinical trial click here.
